Inhibition of marburg virus budding by nonneutralizing antibodiesto the envelope glycoprotein

Journal of Virology

Volumn 86, Issue 24, 2012, Pages 13467-13474

  Kajihara, Masahiro ^a   Marzi, Andrea ^b   Nakayama, Eri ^a   Noda, Takeshi ^c   Kuroda, Makoto ^a   Manzoor, Rashid ^a   Matsuno, Keita ^a   Feldmann, Heinz ^b   Yoshida, Reiko ^a   Kawaoka, Yoshihiro ^c,d,e   Takada, Ayato ^a,f  

^a HOKKAIDO UNIVERSITY   (Japan)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c UNIVERSITY OF TOKYO   (Japan)

^d JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^e UNIVERSITY OF WISCONSIN MADISON   (United States)

^f UNIVERSITY OF ZAMBIA   (Zambia)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; MATRIX PROTEIN; NEUTRALIZING ANTIBODY; NONSTRUCTURAL PROTEIN 4; PROTEIN VP40; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN; VIRUS GLYCOPROTEIN; VIRUS NUCLEOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CELL STRUCTURE; CELL SURFACE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; ELECTRON MICROSCOPY; EMBRYO; FEMALE; HUMAN; HUMAN CELL; INFECTION PREVENTION; MARBURG HEMORRHAGIC FEVER; MARBURG VIRUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; VIRION; VIRUS ENTRY; VIRUS LIKE AGENT; VIRUS NEUTRALIZATION; VIRUS RELEASE; VIRUS VIRULENCE;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CERCOPITHECUS AETHIOPS; FEMALE; GLYCOPROTEINS; HUMANS; MARBURGVIRUS; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; VERO CELLS; VIRAL ENVELOPE PROTEINS;

EBOLA VIRUS; LAKE VICTORIA MARBURGVIRUS;

EID: 84870660384     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01896-12     Document Type: Article

References (53)

1. Corboba P, Grutadauria S, Cuffini C, Zapata M. 2000. Neutralizing monoclonal antibody to the E1 glycoprotein epitope of rubella virus mediates virus arrest in VERO cells. Viral Immunol. 13:83-92.
2. Driscoll DM, Onuma M, Olson C. 1977. Inhibition of bovine leukemia virus release by antiviral antibodies. Arch. Virol. 55:139 -144.
3. DuBridge RB, et al. 1987. Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system. Mol. Cell. Biol. 7:379 -387.
4. Dye JM, et al. 2012. Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. Proc. Natl. Acad. Sci. U. S. A. 109: 5034-5039.
5. Feldmann H, Nichol ST, Klenk HD, Peters CJ, Sanchez A. 1994. Characterization of filoviruses based on differences in structure and antigenicity of the virion glycoprotein. Virology 199:469-473.
6. Feldmann H, Will C, Schikore M, Slenczka W, Klenk HD. 1991. Glycosylation and oligomerization of the spike protein of Marburg virus. Virology 182:353-356.
7. Fujinami RS, Norrby E, Oldstone MB. 1984. Antigenic modulation induced by monoclonal antibodies: antibodies to measles virus hemagglutinin alters expression of other viral polypeptides in infected cells. J. Immunol. 132:2618 -2621.
8. Fujinami RS, Oldstone MB. 1980. Alterations in expression of measles virus polypeptides by antibody: molecular events in antibody-induced antigenic modulation. J. Immunol. 125:78-85.
9. Harty RN. 2009. No exit: targeting the budding process to inhibit filovirus replication. Antiviral Res. 81:189 -197.
10. Harty RN, Brown ME, Wang G, Huibregtse J, Hayes FP. 2000. A PPxY motif within the VP40 protein of Ebola virus interacts physically and functionally with a ubiquitin ligase: implications for filovirus budding. Proc. Natl. Acad. Sci. U. S. A. 97:13871-13876.
11. Jasenosky LD, Neumann G, Lukashevich I, Kawaoka Y. 2001. Ebola virus VP40-induced particle formation and association with the lipid bilayer. J. Virol. 75:5205-5214.
12. Johansson BE, Grajower B, Kilbourne ED. 1993. Infection-permissive immunization with influenza virus neuraminidase prevents weight loss in infected mice. Vaccine 11:1037-1039.
13. Kolesnikova L, Bamberg S, Berghöfer B, Becker S. 2004. The matrix protein of Marburg virus is transported to the plasma membrane along cellular membranes: exploiting the retrograde late endosomal pathway. J. Virol. 78:2382-2393.
14. Kolesnikova L, Berghöfer B, Bamberg S, Becker S. 2004. Multivesicular bodies as a platform for formation of the Marburg virus envelope. J. Virol. 78:12277-12287.
15. Kolesnikova L, Bohil AB, Cheney RE, Becker S. 2007. Budding of Marburgvirus is associated with filopodia. Cell. Microbiol. 9:939 -951.
16. Lee JE, et al. 2008. Structure of the Ebola virus glycoprotein bound to a human survivor antibody. Nature 454:177-182.
17. Lee JE, Saphire EO. 2009. Neutralizing ebolavirus: structural insights into the envelope glycoprotein and antibodies targeted against it. Curr. Opin. Struct. Biol. 19:408-417.
18. Licata JM, Johnson RF, Han Z, Harty RN. 2004. Contribution of Ebola virus glycoprotein, nucleoprotein, and VP24 to budding of VP40 viruslike particles. J. Virol. 78:7344 -7351.
19. Liu Y, Harty RN. 2010. Viral and host proteins that modulate filovirus budding. Future Virol. 5:481-491.
20. Manley K, et al. 2011. Human cytomegalovirus escapes a naturally occurring neutralizing antibody by incorporating it into assembling virions. Cell Host Microbe 10:197-209.
21. Marzi A, et al. 2012. Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever. PLoS One 7:e36192. doi:10.1371/journal.pone.0036192.
22. Matsuno K, et al. 2010. Different potential of C-type lectin-mediated entry between Marburg virus strains. J. Virol. 84:5140 -5147.
23. Nakayama E, Takada A. 2011. Ebola and Marburg viruses. J. Disaster Res. 6:381-389.
24. Nakayama E, et al. 2011. Antibody-dependent enhancement of Marburg virus infection. J. Infect. Dis. 204:S978 -S985. doi:10.1093/infdis/jir334.
25. Nakayama E, et al. 2010. Enzyme-linked immunosorbent assay for detection of filovirus species-specific antibodies. Clin. Vaccine Immunol. 17:1723-1728.
26. Nayak B, et al. 2010. Contributions of the avian influenza virus HA, NA, and M2 surface proteins to the induction of neutralizing antibodies and protective immunity. J. Virol. 84:2408 -2420.
27. Noda T, et al. 2002. Ebola virus VP40 drives the formation of virus-like filamentous particles along with GP. J. Virol. 76:4855-4865.
28. Orvell C, Kristensson K. 1985. The effects of monoclonal antibodies against the hemagglutinin-neuraminidase and fusion protein on the release of Sendai virus from infected cells. Arch. Virol. 86:1-15.
29. Qiu X, et al. 2012. Successful treatment of Ebola virus-infected cynomolgus macaques with monoclonal antibodies. Sci. Transl. Med. 4:138ra81. doi:10.1126/scitranslmed.3003876.
30. Sanchez A, Geisbert TW, Feldmann H. 2007. Filoviridae: Marburg and Ebola viruses, p 1409-1448. In Knipe DM, et al (ed), Fields virology, 5th ed, vol 1. Lippincott Williams & Wilkins, Philadelphia, PA.
31. Schneider-Schaulies S, et al. 1992. Antibody-dependent transcriptional regulation of measles virus in persistently infected neural cells. J. Virol. 66:5534 -5541.
32. Science Council of Japan. 2006. Guidelines for proper conduct of animal experiments. http://www.scj.go.jp/ja/info/kohyo/pdf/kohyo-20-k16-2e.pdf.
33. Shahhosseini S, et al. 2007. Production and characterization of monoclonal antibodies against different epitopes of Ebola virus antigens. J. Virol. Methods 143:29 -37.
34. Shedlock DJ, et al. 2010. Antibody-mediated neutralization of Ebola virus can occur by two distinct mechanisms. Virology 401:228 -235.
35. Shiraki K, et al. 2011. Neutralizing anti-gH antibody of varicella-zoster virus modulates distribution of gH and induces gene regulation, mimicking latency. J. Virol. 85:8172-8180.
36. Simmons G, Wool-Lewis RJ, Baribaud F, Netter RC, Bates P. 2002. Ebola virus glycoproteins induce global surface protein down-modulation and loss of cell adherence. J. Virol. 76:2518 -2528.
37. Takada A. 2012. Filovirus tropism: cellular molecules for viral entry. Front. Microbiol. 3:34. doi:10.3389/fmicb.2012.00034.
38. Takada A, Ebihara H, Jones S, Feldmann H, Kawaoka Y. 2007. Protective efficacy of neutralizing antibodies against Ebola virus infection. Vaccine 25:993-999.
39. Takada A, et al. 2003. Identification of protective epitopes on Ebola virus glycoprotein at the single amino acid level by using recombinant vesicular stomatitis viruses. J. Virol. 77:1069 -1074.
40. Takada A, et al. 2004. Human macrophage C-type lectin specific for galactose and N-acetylgalactosamine promotes filovirus entry. J. Virol. 78:2943-2947.
41. Takada A, et al. 1997. A system for functional analysis of Ebola virus glycoprotein. Proc. Natl. Acad. Sci. U. S. A. 94:14764 -14769.
42. Timmins J, Scianimanico S, Schoehn G, Weissenhorn W. 2001. Vesicular release of Ebola virus matrix protein VP40. Virology 283:1-6.
43. Towner JS, et al. 2009. Isolation of genetically diverse Marburg viruses from Egyptian fruit bats. PLoS Pathog. 5:e1000536. doi:10.1371/ journal.ppat.1000536.
44. Urata S, et al. 2007. Interaction of Tsg101 with Marburg virus VP40 depends on the PPPY motif, but not the PT/SAP motif as in the case of Ebola virus, and Tsg101 plays a critical role in the budding of Marburg virus-like particles induced by VP40, NP, and GP. J. Virol. 81:4895-4899.
45. Urata S, Yasuda J. 2010. Regulation of Marburg virus (MARV) budding by Nedd4.1: a different WW domain of Nedd4.1 is critical for binding to MARV and Ebola virus VP40. J. Gen. Virol. 91:228 -234.
46. Vanderplasschen A, Hollinshead M, Smith GL. 1997. Antibodies against vaccinia virus do not neutralize extracellular enveloped virus but prevent virus release from infected cells and comet formation. J. Gen. Virol. 78: 2041-2048.
47. Volchkov VE, et al. 2000. Proteolytic processing of Marburg virus glycoprotein. Virology 268:1-6.
48. Watanabe S, et al. 2004. Production of novel Ebola virus-like particles from cDNAs: an alternative to Ebola virus generation by reverse genetics. J. Virol. 78:999 -1005.
49. Webster RG, Reay PA, Laver WG. 1988. Protection against lethal influenza with neuraminidase. Virology 164:230 -237.
50. Wilson JA, et al. 2000. Epitopes involved in antibody-mediated protection from Ebola virus. Science 287:1664 -1666.
51. Wool-Lewis RJ, Bates P. 1998. Characterization of Ebola virus entry by using pseudotyped viruses: identification of receptor-deficient cell lines. J. Virol. 72:3155-3160.
52. World Health Organization. 2005. Marburg haemorrhagic fever, Angola. Wkly. Epidemiol. Rec. 80:158-159.
53. Zinnheimer-Dreikorn J, Koschel KP. 1990. Antigenic modulation of measles subacute sclerosing panencephalitis virus in a persistently infected rat glioma cell line by monoclonal anti-haemagglutinin antibodies. J. Gen. Virol. 71:1391-1394.